Introduction {#Sec1}
============

Incretins \[glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP)\] are hormones that stimulate insulin secretion, inhibit glucagon secretion, delay gastric emptying, and decrease appetite \[[@CR1]\]. They also play an important physiological role in regulating both first- and second-phase insulin responses, which are impaired in patients with type 2 diabetes (T2D) \[[@CR2]\]. Recent evidence suggests an approximate 60% reduction in the magnitude of incretin effects in individuals with T2D \[[@CR2]\].

Two classes of incretin-based therapies are currently available: injectable GLP-1 receptor agonists (GLP-1RAs) and oral dipeptidyl peptidase-4 inhibitors (DPP-4 inhibitors) \[[@CR3]--[@CR11]\]. The efficacy, tolerability, and clinical use of these agents are described in Tables [1](#Tab1){ref-type="table"}, [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"} \[[@CR5]--[@CR33]\]. Currently available GLP-1RAs include liraglutide, exenatide twice daily (exenatide BID), and exenatide once weekly \[exenatide extended release (EQW)\]. Liraglutide and exenatide BID are administered by pen devices; EQW is administered as a suspension with a 23-gage needle and syringe and requires reconstitution. GLP-1RAs enhance glucose-dependent insulin secretion by mimicking the glucoregulatory effects of endogenous GLP-1 and by providing pharmacological (high) levels of GLP-1 activity, and also suppress glucagon release (Fig. [1](#Fig1){ref-type="fig"}) \[[@CR1], [@CR34], [@CR35]\]. In contrast, DPP-4 inhibitors prevent enzymatic inactivation of endogenous GLP-1, resulting in prolonged availability of physiological levels of native GLP-1 and GIP and modest receptor activation \[[@CR1]\]. Sitagliptin, saxagliptin, and linagliptin are the DPP-4 inhibitors currently available in the United States. A fourth DPP-4 inhibitor, alogliptin, has recently been approved. All are administered orally once daily, with or without food.Table 1Currently approved incretin-based therapies \[[@CR5]--[@CR11]\]IndicationsContraindicationsWarnings and precautions\*Most common adverse reactions^†^DosingDose adjustment in renal impairment^**‡**^GLP-1RAs Exenatid**e**Use as monotherapy, in combination with OADs and insulinSerious hypersensitivity to exenatide or product componentsPancreatitis, hypoglycemia (with insulin and sulfonylurea), use with severe renal impairment and ESRD, severe GI disease, hypersensitivity to exenatideNausea, hypoglycemia, vomiting, diarrhea, feeling jittery, dizziness, headache, dyspepsia, constipation, astheniaStarting dose 5 mcg twice daily; titrate to 10 mcg twice daily after 1 month; exenatide is administered twice daily, 1 h before morning and evening mealsNone; exenatide should not be used in severe renal impairment or ESRD Exenatide Extended Release (EQW)Use as monotherapy and in combination with OADsPersonal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 or serious hypersensitivity to exenatide or product componentsThyroid C-cell tumors, pancreatitis, hypoglycemia (with insulin and sulfonylurea), use in severe renal impairment and ESRD, severe GI disease, hypersensitivity to exenatideNausea, diarrhea, headache, vomiting, constipation, injection site pruritus, injection site nodule, and dyspepsia2 mg once weekly without regard to mealsNone; should not be used in severe renal impairment or ESRD LiraglutideUse as monotherapy, in combination with OADs and insulinPersonal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 or serious hypersensitivity to liraglutide or product componentsThyroid C-cell tumors, pancreatitis, serious hypoglycemia (with insulin and sulfonylurea), use in renal impairment, hypersensitivity to liraglutideHeadache, nausea, diarrhea, and anti-liraglutide antibody formationStarting dose 0.6 mg/day for 1 week; 1.2 mg/day thereafter; if acceptable glycemic control is not reached, dose can be increased to 1.8 mg/day; Liraglutide is administered once daily independently of mealsNoneDPP-4 inhibitors SitagliptinUse as monotherapy, in combination with OADs and insulinSerious hypersensitivity to sitagliptinAcute pancreatitis, acute renal failure, hypoglycemia (with insulin and a sulfonylurea), allergy/hypersensitivityUpper respiratory tract infection (URI), nasopharyngitis, and headache; hypoglycemia when used with insulin/sulfonylurea100 mg once daily, with or without food50 mg once daily in moderate renal impairment; 25 mg once daily in severe renal impairment and ESRD SaxagliptinUse as monotherapy, in combination with OADs and insulinSerious hypersensitivity to saxagliptinAcute pancreatitis, hypoglycemia (with insulin and a sulfonylurea), hypersensitivity to saxagliptinURI, urinary tract infection (UTI), and headache; hypoglycemia when used with insulin/sulfonylurea; peripheral edema when used with a TZDN/A2.5 mg once daily in moderate or severe renal impairment or ESRD LinagliptinUse as monotherapy, in combination with OADs and insulinSerious hypersensitivity to linagliptinHypoglycemia (with sulfonylurea/insulin)Nasopharyngitis; hypoglycemia when used with sulfonylureaN/ANone AlogliptinUse as monotherapy, in combination with OADs and insulinSerious hypersensitivity to alogliptinAcute pancreatitis, hypersensitivity, hepatic effects, hypoglycemia (with insulin and a sulfonylurea)Nasopharyngitis, headache, URIN/A12.5 mg once daily in moderate renal impairment; 6.25 mg once daily in severe impairment and ESRD*CrCl* creatine clearance, *DPP-4 inhibitors* dipeptidyl peptidase-4 inhibitors, *ESRD* end-stage renal disease, *GI* gastrointestinal, *GLP-1RAs* glucagon-like peptide-1 receptor agonists, *OADs* oral antidiabetic drugs, *TZD* thiazolidinediones\*All antidiabetes agents carry a warning regarding the lack of clinical studies providing conclusive evidence of macrovascular risk reduction with their use^†^Reported in ≥4% (alogliptin) or ≥5% (exenatide, EQW, liraglutide, sitagliptin, saxagliptin, linagliptin) and more frequently than in patients treated with placebo^**‡**^Moderate renal impairment: CrCl ≥30 mL/min and \<50 mL/min (sitagliptin) or \<60 mL/min (alogliptin); severe renal impairment: CrCl \<30 mL/minTable 2Glycemic effects of GLP-1RAs vs DPP-4 inhibitors in randomized clinical trials conducted in patients with T2DDrug comparison/study design and durationPatient populationBackground medication (s)∆ A1C (%)∆ FPG (mmol/L unless otherwise noted)∆ 2-h PPG (mmol/L) (mg/dL)Hypoglycemic episodes (%) (event/person/year)TreatmentGLP-1RADPP-4 inhibitorGLP-1RADPP-4 inhibitorGLP-1RADPP-4 inhibitorGLP-1RADPP-4 inhibitorLiraglutide (1.2 or 1.8 mg/day) vs sitagliptin 26-week open-label study \[[@CR12]\]Patients with inadequate glycemic control on metforminMetformin−1.24\*\
−1.50\*−0.9−1.87\*\
−2.14\*−0.83NR5% (0.370)5% (0.106)At 26 weeks; \**P* \< 0.0001 for comparison of each dose of liraglutide to sitagliptin26-week extension study of liraglutide (1.2 or 1.8 mg/day) vs. sitagliptin \[[@CR13]\]Patients with inadequate glycemic control on metforminMetformin−1.29\*\
−1.51\*−0.88−1.71\*\
−2.04\*−0.59NR8.1% (0.143)\
8.3% (0.154)6.4% (0.170)At 52 weeks; \**P* \< 0.0001 for comparison of each dose of liraglutide to sitagliptinSecond 26-week extension in which patients on sitagliptin were switched to liraglutide \[[@CR14]\]Patients with inadequate glycemic control on metforminMetformin−0.9\*\
−1.3\*−0.2\
−0.5 after switch to liraglutide^†^−1.3\*\
−1.7\*−0.8\
−1.4 after switch to liraglutide^†^NR(0.156)^‡^\
(0.130)^‡^(0.031)^§^\
(0.060)^§^\*Change from baseline (week 0)\
^†^Change after switch to liraglutide at week 52\
^‡^Rates of minor hypoglycemia from week 0 to week 72; 1 patient on liraglutide 1.2 mg/day experienced 2 major episodes\
^§^Rates of minor hypoglycemia after switch to liraglutide; no episodes of major hypoglycemia were reportedExenatide vs sitagliptin vs background medication alone; 4-week open-label study \[[@CR15]\]−1.8\*^†^−1.5\*NRNRNR\**P* \< 0.0001 for comparison with baseline; ^†^ *P* = 0.0154 for comparison with metformin + insulin glargine (−1.23%)Exenatide vs sitagliptin plus exenatide; 20-week, double-blind, parallel-group study \[[@CR16]\]Patients with inadequate glycemic control on metformin + sitagliptinMetformin−0.38\*−0.680.06\*−0.55−1.55\*−2.100.8%1.6%\**P* \< 0.05 for comparison of exenatide BID with exenatide BID + sitagliptinExenatide vs sitagliptin;\
2-week, double-blind crossover \[[@CR17]\]Patients on a stable regimen of metforminMetforminNR−15−19112 mg/dL\*37 mg/dL1 minor episodeNR\**P* \< 0.0001 for comparison of exenatide BID to sitagliptinExenatide vs sitagliptin;\
8-week, double-blind crossover \[[@CR18]\]Patients on a stable regimen of metformin or TZDMetformin or TZDNR−1.6\*−1.6−6.0−2.5NR\**P* \< 0.01 for comparison of exenatide BID to sitagliptinEQW vs sitagliptin vs pioglitazone;\
26-week, double-blind, superiority study \[[@CR19]\]Patients on a stable regimen of metforminMetformin−1.5\*−0.9−1.8^†^−0.9NR1%3%At 26 weeks; \**P* \< 0.0001, ^†^ *P* = 0.038 for comparison of EQW to sitagliptin26-week open-label extension in which patients previously on sitagliptin or pioglitazone switched to exenatide \[[@CR20]\]None: all oral medications, including metformin, were stopped in the extension−0.06−0.31\* after switch to exenatide ER−0.2−0.7\* after switch to EQWNR1%2% after switch to EQW\*At 52 weeks, *P* \< 0.05 for comparison with blinded period (weeks 0--26)EQW vs sitagliptin vs metformin vs pioglitazone;\
26-week noninferiority \[[@CR21]\]Drug-naive patientsNone−1.53\*−1.15−2.3\*−1.1NRMinor: 5.2%\
Major: 2.0%3.1%\**P* \< 0.001 for comparison of exenatide BID to sitagliptin; NS for comparison with metformin or pioglitazone∆ change, *A1C* hemoglobin A1c, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *TZD* thiazolidinedionesTable 3Glycemic effects of longer-acting vs shorter-acting GLP-1RAs in randomized clinical trials conducted in patients with T2DDrug comparison/study design and durationPatient populationBackground medication(s)∆ A1C (%)∆ FPG (mmol/L unless otherwise noted)∆ 2-h PPG (mmol/L) (mg/dL)Hypoglycemic episodes (%) (event/person/year)TreatmentEQWEBIDLQDEQWEBIDLQDEQWEBIDLQDEQWEBIDLQDLiraglutide vs exenatide; 26-week, open-label, parallel group (LEAD-6) \[[@CR22]\]Patients not adequately controlled on maximally tolerated doses of metformin, sulfonylurea, or bothMetformin, sulfonylurea, or both--−0.79−1.12\*--−0.6−1.61--Favored exenatide\*--2.6 EPY1.93 EPY^†^At 26 weeks; \**P* \< 0.0001 compared with exenatide; ^†^ *P* = 0.0131 compared with exenatide14-week, open-label extension in which patients on exenatide BID switched to liraglutide\
(LEAD-6) \[[@CR23]\]--−0.32\* after switch to liraglutide−0.06--−0.9\* after switch to liraglutide−0.2---- after switch to liraglutide----−0.9\* after switch to liraglutide−0.4^†^At 40 weeks; \**P* \< 0.0001 vs exenatide BID for weeks 0--26; ^†^ *P* = 0.0089 vs liraglutide for weeks 0--26Liraglutide vs. EQW;\
26-week, open-label, parallel group (DURATION-6) \[[@CR24]\]Patients on oral antidiabetic agentsMetformin, sulfonylurea, and/or pioglitazone−1.28--−1.48NR--NRNR--NR10.8%--8.9%Exenatide vs. EQW;\
30-week, open-label noninferiority (DURATION-1) \[[@CR25]\]Patients who were drug naive or on 1 or more antidiabetic agentsNone or metformin, sulfonylurea, TZD, or any 2 agents−1.9\*−1.5--−2.3^†^−1.4--−5.3^§^−6.9--14.5%15.4%--At 30 weeks \**P* = 0.0023, ^†^ *P* \< 0.001, ^§^ *P* = 0.0124 for comparison of exenatide BID to once-weekly exenatide22-week extension in which patients on exenatide BID switched to EQW (DURATION-1) \[[@CR26]\]Patients who were drug naive or on one or more antidiabetic agentsNone or metformin, sulfonylurea, TZD, or any two agents−2.0%−2.0% after change to EW--−47 mg/dL−43 mg/dL after change to EW--NRNR--NRNR--Exenatide vs. EQW;\
24-week open-label (DURATION-5) \[[@CR27]\]Patients who were drug naive or on one or more antidiabetic agentsNone or metformin, sulfonylurea, TZD, or any combination−1.6\*−0.9--−1.9^†^\
−35−0.7\
−12--NRNR--6.8%5.4%--\**P* \< 0.0001, ^†^ *P* = 0.0008 compared with exenatide BID∆ change, *A1C* hemoglobin A1c, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *TZD* thiazolidinedionesTable 4Glycemic effects of GLP-1RAs plus insulin in randomized clinical trials conducted in patients with T2DDrug comparison/study design and durationPatient populationBackground medication(s)∆ A1C (%)∆ FPG (mmol/L unless otherwise noted)∆ 2-h PPG (mmol/L) (mg/dL)Hypoglycemic episodes (%) (event/person/year)TreatmentGLP-1RAGLP-1RA + InsulinGLP-1RAGLP-1RA + InsulinGLP-1RAGLP-1RA + InsulinGLP-1RAGLP-1RA + InsulinLiraglutide vs liraglutide + insulin\
Liraglutide; 12-week lead, in which liraglutide was added to metformin\[[@CR28]\]Insulin-naive patients on metformin or metformin/sulfonylurea combinationMetformin−1.3 (O)\
−0.7 (RC)\
−0.6 (RT)--−2.0 (O)\
−1.5 (RC)\
−1.0 (RT)--NR--6.2% (O)\
(0.38)\
0% (RC)\
(0)\
4.3% (RT)\
(0.21)--At 12 weeks, controlled patients were included in an observational group (O) and continued in the extension. Inadequately controlled patients were randomized to continued therapy (randomized control, RC) or to additional treatment with insulin detemir (randomized treatment, RT)26-week, open-label extension in which patients controlled by liraglutide/metformin combination continued same treatment; inadequately controlled patients were randomized to continue same treatment or to receive insulin in addition to combination \[[@CR28]\]−1.1 (O)\
−0.8 (RC)−1.1\* (RT)−2.1 (O)\
−2.3 (RC)−3.1^†^ (RT)NRNR4.2% (O)\
(0.13)\
1.3% (RC)\
(0.03)9.2%^‡^ (RT)\
(0.29)\**P* \< 0.0001; ^†^ *P* = 0.03; ^‡^ *P* = 0.004 for RC vs RT comparisons at end of 26-week extensionExenatide BID vs placebo;\
30-week, double-masked, placebo- controlled \[[@CR29]\]Patients on insulin alone or in combination with metformin or pioglitazone or bothInsulin, alone or in combination with metformin or pioglitazone or both--−1.74\*--−1.6 NS--NR--1.4 EPY\**P* \< 0.001 for comparison with placebo (−1.04); *NS* not significantly different from placebo (−1.5)∆ change, *A1C* hemoglobin A1c, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *TZD* thiazolidinedionesTable 5Glycemic effects of DPP-4 inhibitors plus insulin in randomized clinical trials conducted in patients with T2DDrug comparison/study design and durationPatient populationBackground medication(s)∆ A1C (%)∆ FPG (mmol/L unless otherwise noted)∆ 2-h PPG (mmol/L) (mg/dL)Hypoglycemic episodes (%) (event/person/year)TreatmentDPP-4 inhibitorDPP-4 inhibitor + InsulinDPP-4 inhibitorDPP-4 inhibitor + InsulinDPP-4 inhibitorDPP-4 inhibitor + InsulinDPP-4 inhibitorDPP-4 inhibitor + InsulinLinagliptin vs placebo;\
1-year, randomized, double-blind study \[[@CR30]\]Patients with T2D and severe renal impairmentInsulin, sulfonylurea, glitazone, alpha-glucosidase inhibitor + glinide--−0.72\*NRNRNRNR--83.7%\**P* \< 0.0001 for treatment with linagliptin + background meds compared with placebo + background medsSitagliptin vs increasing dose of insulin; 24-week, parallel group \[[@CR31]\]Patients uncontrolled on insulin aloneInsulin--−0.63\*--NS--−74.5 mg/dL^†^--7.0^§^ EPY\**P* = 0.01 for comparison with increasing dose of insulin (−0.22); ^†^ *P* \< 0.001 for comparison with increasing dose of insulin (−21.7); *NS* not significantly different between treatments (values not reported); ^§^ *P* \< 0.05 vs increasing dose of insulin (14.3 EPY)Sitagliptin vs placebo;\
24-week, double-blind, placebo-controlled, parallel group \[[@CR32]\]Patients uncontrolled on insulin alone or in combination with metforminInsulin, alone or in combination with metformin--−0.6\*--−18.5^†^--−30.9 mg/dL--16%^§^\**P* \< 0.001 for comparison with placebo (0); ^†^ *P* ≤ 0.001 for comparison with placebo (−3.5 for FSG and +5.2 for PPG); ^§^ *P* \< 0.003 compared with placeboSaxagliptin vs placebo;\
24-week, double-blind, placebo-controlled, parallel group \[[@CR33]\]Patients uncontrolled on insulin alone or in combination with metforminInsulin, alone or in combination with metformin--−0.73\*--−0.22--−1.3^†^--Minor: 5.3%\
Major: 1.0%At week 24, \**P* \< 0.0001 compared with placebo; ^†^ *P* = 0.0016 compared with placebo∆ change, *A1C* hemoglobin A1c, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *TZD* thiazolidinedionesTable 6Extraglycemic effects of GLP-1RAs vs DPP-4 inhibitors in randomized clinical trials conducted in patients with T2DDrug comparison/study design and duration∆ BW (kg)∆ β**-**cell function (HOMA-B) (%)∆ SBP (mmHg)TreatmentGLP-1RADPP-4 inhibitorGLP-1RADPP-4 inhibitorGLP-1RADPP-4 inhibitorLiraglutide (1.2 or 1.8 mg/day) vs sitagliptin;\
26-week, open-label study with 26-week extension \[[@CR12]\]−2.86\*\
−3.38\*−0.9627.23\*\
28.70\*4.18−0.55\
−0.72−0.94At 26 weeks; \**P* \< 0.0001 for comparison of each dose of liraglutide to sitagliptinFirst 26-week extension \[[@CR13]\]−2.78\*\
−3.68\*−1.1622.58^†^\
25.76^†^3.98−0.37\
−2.55−1.03At 52 weeks; \**P* \< 0.0001, ^†^ *P* \< 0.001 for comparison of each dose of liraglutide to sitagliptinSecond 26-week extension in which patients on sitagliptin were switched to liraglutide \[[@CR14]\]−2.6\
−3.1−1.6\*\
−2.5\* after switch to liraglutideImprovements observed with both dosesSignificant increases observed with both doses after switch to liraglutideNo notable changes observedNo significant changes observed after switch to liraglutideAt 78 weeks; \**P* \< 0.0001 for comparison of each dose of liraglutide to sitagliptinExenatide vs sitagliptin vs background medication alone; 4-week, open-label study \[[@CR15]\]−0.90.4NRNRNRNR\**P* \< 0.037 for comparison with metformin + insulin glargine (0.4)Exenatide vs sitagliptin plus exenatide;\
20-week, double-blind, parallel-group study \[[@CR16]\]−2.58−2.20NRNR−2.3−0.8Exenatide vs sitagliptin;\
2-week, double-blind crossover \[[@CR17]\]−0.8\*−0.3NRNRNRNR\**P* = 0.0056 for comparison of exenatide BID to sitagliptinExenatide vs sitagliptin;\
8-week, double-blind crossover \[[@CR18]\]−1.37\*−0.8932.920.8−2.5−2.0\**P* \< 0.05 for comparison of exenatide BID to sitagliptinEQW vs sitagliptin vs pioglitazone;\
26-week, double-blind, superiority study \[[@CR19]\]−2.3\*−0.8NRNRDecreased^†^No changeAt 26 weeks; \**P* = 0.0002 for comparison of exenatide BID to sitagliptin; ^†^ *P* = 0.0055 for difference in SBP (−4 mmHg)26-week, open-label extension in which patients previously on sitagliptin or pioglitazone switched to exenatide \[[@CR20]\]0.7\*−1.1\* after switch to EQWNRNR−0.9−2.7\* after switch to EQWAt 52 weeks, \**P* \< 0.05 comparison with blinded period (weeks 0--26)EQW vs sitagliptin vs metformin vs pioglitazone; 26-week noninferiority \[[@CR21]\]−2.0\*−0.8Ratio (baseline to endpoint): +1.8^†^Ratio (baseline to endpoint): +1.3NRNR\**P* \< 0.001 for comparison of EQW to sitagliptin or pioglitazone; NS for comparison with metformin; ^†^ *P* \< 0.001 for comparison of EQW to sitagliptin, pioglitazone, or metformin∆ change, *A1C* hemoglobin A1c, *BW* body weight, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *HOMA-B* homeostatic model assessment-B, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *SBP* systolic blood pressure, *TZD* thiazolidinedionesTable 7Extraglycemic effects of longer-acting vs shorter-acting GLP-1RAs in randomized clinical trials conducted in patients with T2DDrug comparison/study design and duration∆ BW (kg)∆ β**-**cell function(HOMA-B) (%)∆ SBP (mmHg)TreatmentEQWEBIDLQDEQWEBIDLQDEQWEBIDLQDLiraglutide vs exenatide;\
26-week, open-label, parallel group (LEAD-6) \[[@CR22]\]--−2.87−3.24--2.7432.12\*--−2.00−2.51At 26 weeks; \**P* \< 0.0001 compared with exenatide14-week, open-label extension in which patients on exenatide BID switched to liraglutide (LEAD-6) \[[@CR23]\]--−0.9\* after switch to liraglutide−0.4^†^--14.5^‡^ after switch to liraglutideNR--−3.8\* after switch to liraglutide−2.2At 40 weeks; \**P* \< 0.0001 compared with exenatide at 26 weeks; ^†^ *P* = 0.0089 compared with liraglutide at 26 weeks; ^‡^ *P* = 0.001 compared with exenatide at 26 weeks; ^§^ *P* = 0.0128 compared with exenatide at 26 weeksLiraglutide vs. EQW; 26-week, open-label, parallel group (DURATION-6) \[[@CR24]\]−2.68--−3.58NR--NR−2.5--−3.5Exenatide BID vs. EQW;\
30-week, open-label noninferiority (DURATION-1) \[[@CR25]\]−3.7−3.6--NRNR--−4.7−3.4--22-week extension in which patients on exenatide BID switched to exenatide ER (DURATION-1) \[[@CR26]\]−4.1−4.5 after switch to exenatide ER--NRNR--−6.2−3.8 after switch to exenatide ER--Exenatide BID vs. EQW;\
24-week, open-label (DURATION-5)\[[@CR27]\]−2.3−1.4--NRNR--−2.9−1.2--∆ change, *A1C* hemoglobin A1c, *BW* body weight, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *HOMA-B* homeostatic model assessment-B, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *SBP* systolic blood pressure, *TZD* thiazolidinedionesTable 8Extraglycemic effects of GLP-1RAs plus insulin in randomized clinical trials conducted in patients with T2DDrug comparison/study design and duration∆ BW (kg)∆ β**-**cell Function (HOMA-B) (%)∆ SBP (mmHg)TreatmentGLP-1RAGLP-1RA + InsulinGLP-1RAGLP-1RA + InsulinGLP-1RAGLP-1RA + InsulinLiraglutide vs liraglutide + insulin;\
12-week lead-in which liraglutide was added to metformin \[[@CR28]\]−4.4 (O)\
−3.5 (RC)\
−3.5 (RT)--NR--NR--At 12 weeks, controlled patients were included in an observational group (O) and continued in the extension. Inadequately controlled patients were randomized to continued therapy (randomized control, RC) or to additional treatment with insulin detemir (randomized treatment, RT)26-week, open-label extension in which patients controlled by liraglutide/metformin combination continued same treatment; patients not adequately controlled by liraglutide/metformin combination were randomized to continue same treatment or to receive insulin in addition to combination \[[@CR28]\]−4.8 (O)\
−4.7 (RC)−4.0\* (RT)NRNR−3.3 (O)\
−3.1 (RC)−1.7 (RT)\**P* = 0.03; ^‡^ *P* = 0.004 for RC vs RT comparisons at end of 26-week extensionExenatide BID vs placebo; 30-week, double-masked, placebo-controlled trial in patients on background therapy with insulin glargine alone or in combination with metformin and/or pioglitazone \[[@CR29]\]--−1.78\*--NR--−2.7^†^\**P* \< 0.001 for comparison with placebo (+0.96); *P* = 0.01 for comparison with placebo (+1.7)∆ change, *A1C* hemoglobin A1c, *BW* body weight, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *HOMA-B* homeostatic model assessment-B, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *SBP* systolic blood pressure, *TZD* thiazolidinedionesTable 9Extraglycemic effects of DPP-4 inhibitors plus insulin in randomized clinical trials conducted in patients with T2DDrug comparison/study design and duration∆ BW (kg)∆ β-cell function (HOMA-B) (%)∆ SBP (mmHg)TreatmentDPP-4 inhibitorDPP-4 inhibitor + InsulinDPP-4 inhibitorDPP-4 inhibitor + InsulinDPP-4 inhibitorDPP-4 inhibitor + InsulinLinagliptin vs placebo; 1-year, randomized, double-blind, placebo-controlled study in patients with T2D and severe renal impairment \[[@CR30]\]--−1.83--NR--NRSitagliptin vs placebo;\
24-week, parallel group \[[@CR31]\]--−0.7\*--NR--NR\**P* \< 0.05 vs stable dose of insulin alone (+1.1 kg)Sitagliptin vs placebo;\
24-week, double-blind, placebo-controlled, parallel group \[[@CR32]\]--+0.1 NS--NR--NRNS---not significantly different from placebo (+0.1)Saxagliptin vs placebo\
24-week, double-blind, placebo-controlled, parallel group \[[@CR33]\]--−0.39--−1086.8\* (304.25)NRNR\*Adjusted mean change from baseline (SE) in postprandial glucagon AUC (pg min/mL)∆ change, *A1C* hemoglobin A1c, *BW* body weight, *DPP-4 inhibitor* dipeptidyl peptidase-4 inhibitor, *EBID* exenatide twice daily, *EPY* events/person/year, *EQW* exenatide extended release, *FPG* fasting plasma glucose, *GLP-1RA* glucagon-like peptide-1 receptor agonist, *HOMA-B* homeostatic model assessment-B, *NR* not reported, *NS* not significant, *LQD* liraglutide once daily, *PPG* postprandial glucose, *SBP* systolic blood pressure, *TZD* thiazolidinedionesFig. 1Mechanism of Action of GLP-1RAs and DPP-4 inhibitors. *DPP-4 inhibitors* dipeptidyl peptidase-4 inhibitors, *GIP* glucose-dependent insulinotropic polypeptide, *GLP-1* glucagon-like peptide-1. Reprinted with permission from McDougall et al \[[@CR35]\]. Drugs for diabetes: part 5. DPP-4 inhibitors

Incretin-based therapies target most of the dysfunctional organ systems in T2D, potentially improve β-cell function \[[@CR18], [@CR22], [@CR36]\], have minimal hypoglycemia risk, and are either weight neutral \[[@CR31]\] or induce weight loss \[[@CR15], [@CR29], [@CR37]--[@CR43]\]. However, differences in the mechanisms of action and pharmacodynamics/pharmacokinetics, between and within these classes, can result in important differences in fasting plasma glucose (FPG), postprandial glucose (PPG), body weight, β-cell function, blood pressure (BP), and safety and tolerability \[[@CR44]\], as found in randomized head-to-head clinical trials (Tables [2](#Tab2){ref-type="table"}, [3](#Tab3){ref-type="table"}, [4](#Tab4){ref-type="table"}, [5](#Tab5){ref-type="table"}, [6](#Tab6){ref-type="table"}, [7](#Tab7){ref-type="table"}, [8](#Tab8){ref-type="table"}, [9](#Tab9){ref-type="table"} \[[@CR12]--[@CR33]\]). Numerous reviews have examined the efficacy and tolerability of GLP-1RAs and DPP-4 inhibitors based on the results from randomized controlled trials (RCTs) \[[@CR34], [@CR45]--[@CR47]\], but few have focused on comparisons among incretin agents. Moreover, in clinical practice, the appropriate choice of incretin therapy for a given patient is not always clear.

Effective evidence-based decision making requires the integration of clinical experience with the best available clinical evidence, provided by data from either RCTs or systematic research and patient preference \[[@CR48], [@CR49]\]. While clinical trials are conducted in highly selective patient populations with limited strategies, treatment of T2D in clinical practice should reflect an individualized, patient-centered approach that considers the preferences, needs, and values of individual patients \[[@CR3]\], as indicated by recent treatment guidelines \[[@CR3], [@CR4]\]. This review examines the clinical evidence surrounding the use of GLP-1RAs and DPP-4 inhibitors in the context of more than 25 years in a general endocrinology practice. Approximately 50--60% of patients treated in this setting have T2D. It is the objective of this analysis to help clinicians both individualize and optimize incretin therapy in appropriate candidates throughout the progression of T2D.

Methods {#Sec2}
=======

A PubMed literature search was conducted for randomized, head-to-head, comparative studies published between 2000 and 2012 including GLP-1RAs and DPP-4 inhibitors. In addition, randomized, controlled studies for monotherapy and combination therapy published between 2000 and 2012 and internal references on incretins and incretin-based therapies were considered. Specific search terms included glucagon-like peptide-1, GLP-1RAs, exenatide, liraglutide, dipeptidyl peptidase 4, DPP-4 inhibitors, sitagliptin, saxagliptin, and linagliptin.

Compliance with Ethics Guidelines {#Sec3}
---------------------------------

The analysis in this article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by the author.

Role of Incretin Therapies in Diabetes Management {#Sec4}
=================================================

Guidelines currently include incretin therapies at all stages of pharmacologically treated T2D \[[@CR3], [@CR4]\]. They are recommended for initial therapy (usually in combination with metformin and also as monotherapy in some patients), as add-on therapy to oral agents, and even in combination with insulin with or without additional therapies \[[@CR3], [@CR4], [@CR50]\].

Newly Diagnosed, Treatment-Naive Patients {#Sec5}
=========================================

Recommendations for the initial use of metformin in newly diagnosed patients are nearly universal, unless it is contraindicated. However, some patients with high hemoglobin A~1c~ (A1C) at diagnosis are unlikely to achieve their individualized glycemic goals on metformin alone and may require initial combination therapy, which should include classes of medications with complementary modes of action \[[@CR4]\] to effectively target the underlying multiorgan pathophysiology of T2D. Balancing adverse events (AEs) and treatment benefits, particularly the risk for hypoglycemia, is also important. One important option for initial combination therapy is metformin with a GLP-1RA or a DPP-4 inhibitor.

Data on initial combination therapy with GLP-1RAs and metformin in treatment-naive patients inadequately controlled on diet and exercise alone are limited, and no studies have compared initial combination therapy with metformin and GLP-1RAs or DPP-4 inhibitors. However, initial combination therapy with metformin and sitagliptin, saxagliptin, or linagliptin has been evaluated in several clinical trials \[[@CR51]--[@CR53]\]. In these trials, mean A1C reductions with initial combination therapy with a DPP-4 inhibitor and metformin 2,000 mg/day ranged from 1.7 to 2.5%. DPP-4 inhibitors were generally well tolerated in these trials. Rates of hypoglycemia were low and AEs occurred at a similar frequency across groups in each study.

GLP-1RAs and metformin as initial therapy have not been extensively evaluated, but GLP-1RAs have been studied as add-on therapy to metformin in numerous trials. Results from these trials may provide some insight as to the potential effects of this combination as initial therapy. Such trials have demonstrated reductions in A1C of 0.8--1.5%, with weight loss of 2.3--2.8 kg \[[@CR19], [@CR54], [@CR55]\]. Comparative data on the relative impact of incretin therapies among patients inadequately controlled on metformin will be considered later in the manuscript.

Clinical Experience with Incretins as Initial Therapy {#Sec6}
-----------------------------------------------------

In newly diagnosed patients requiring more than metformin to get to their individualized A1C goal, the choice for incretin therapy depends on several factors, including baseline A1C, body mass index, and comorbidities. GLP-1RA plus metformin for obese patients with high A1C typically works well. It is possible to achieve glycemic targets in patients at A1C 10% with GLP-1RAs and metformin \[[@CR22]\]. In addition, the sustained weight loss associated with GLP-1RAs in clinical trials---which can be impressive in some patients---is beneficial to many organ systems \[[@CR26]\]. Because of the limited glucose-lowering potential of DPP-4 inhibitors, metformin with a DPP-4 inhibitor in patients with baseline A1C ≥10% will not get most patients to their goal. Although there is evidence suggesting that DPP-4 inhibitors are less effective in patients with A1C \<8% \[[@CR56]\], DPP-4 inhibitors can be used in patients with lower A1C when they are of normal weight, particularly when they resist injections.

For patients with high A1C, symptoms of hyperglycemia, and significant glucotoxicity, the use of insulin is recommended in current treatment guidelines. In the author's clinical experience, patients can be weaned off insulin, as glucotoxicity abates, and initiated on metformin and a GLP-1RA. While clinical data on this approach are limited, it has been successful in the author's practice.

Incretin Agents as Monotherapy {#Sec7}
==============================

There are some newly diagnosed patients in whom metformin is inappropriate or contraindicated. Incretin-based therapies may be a useful option in this population, which includes patients with moderate-to-severe renal impairment or heart failure.

However, patients with severe renal impairment or end-stage renal disease (ESRD) may also be poor candidates for some incretin therapies. Because they are cleared through the kidney, exenatide BID and EQW should not be used in this population \[[@CR5], [@CR7]\]. Although liraglutide is not cleared by renal mechanisms and no differences in safety and efficacy were found in patients with mild renal impairment in a meta-analysis of the Liraglutide Effect and Action in Diabetes (LEAD) clinical trial program \[[@CR57]\], caution and careful monitoring should still be used when initiating liraglutide in such patients \[[@CR7]\]. Sitagliptin, saxagliptin, and alogliptin, but not linagliptin, require dose reductions in patients with renal impairment or ESRD \[[@CR8]--[@CR11]\].

Although data from head-to-head studies of incretin therapies in drug-naive patients with T2D are relatively rare, and no studies have directly compared different DPP-4 inhibitors, the limited comparisons between GLP1-RAs and DPP-4 inhibitors and between various GLP-1RAs can help guide the physician in their choice of incretin therapy, if metformin is not an option.

Data from RCTs comparing EQW with sitagliptin monotherapy showed significantly greater reductions in FPG, A1C, and body weight, and showed that a significantly higher proportion of patients achieved a target A1C level of \<7.0% or ≤6.5%, with EQW. Moreover, there were no significant differences between EQW and metformin monotherapy on reductions in FPG or A1C or on the proportion of patients achieving a target A1C level of \<7.0% \[[@CR21]\], suggesting similar outcomes.

Among patients who managed their diabetes with diet and exercise alone, EQW provided significantly greater reduction in A1C, FPG, and weight compared with exenatide BID. A significantly higher proportion of patients achieved target A1C levels of \<7.0% and ≤6.5% with EQW \[[@CR27]\]. Few head-to-head data on the use of liraglutide compared with other incretin agents in treatment-naive patients are available. However, patients treated with liraglutide monotherapy showed significantly greater reductions in A1C from baseline, compared with glimepiride \[[@CR58], [@CR59]\].

Clinical Experience with Incretins in Monotherapy {#Sec8}
-------------------------------------------------

Although prescribing information for liraglutide or EQW advises against using these agents as first-line therapy, they are typically my preferred alternative to metformin if metformin cannot be used. GLP-1RAs may be particularly suitable because they are effective, may facilitate weight loss, and are associated with a low risk of hypoglycemia. When considering GLP-1RAs, the author's patients usually receive the longer-acting GLP-1RAs, liraglutide and EQW, instead of exenatide BID, because they are dosed less frequently and have a superior effect on fasting glucose \[[@CR22], [@CR27]\].

In patients with moderate-to-severe renal impairment who require A1C reductions \>1% or who would benefit from weight loss, liraglutide is preferred because exenatide BID and EQW should not be used in such patients, but it should be used with caution \[[@CR5]--[@CR7]\]. Linagliptin or reduced-dose sitagliptin or saxagliptin is each a useful option in nonobese patients and/or if a patient with renal insufficiency requires ≤1% A1C reduction \[[@CR60]\]. DPP-4 inhibitors may be particularly appropriate as initial therapy in frail or slim elderly patients with renal impairment, moderately elevated A1C, and elevated PPG without a substantially elevated FPG \[[@CR60]\].

Incretins, including GLP-1RAs, are also useful in patients who cannot tolerate the gastrointestinal (GI) side effects of metformin. In the author's experience, GI symptoms with GLP-1RAs are self-limiting and disappear over time, unlike the GI symptoms often observed with metformin. In elderly patients with severe anorexia with metformin monotherapy, monotherapy with a DPP-4 inhibitor is an important option.

Sulfonylureas may also be an option for patients who refuse incretin therapy, but their potential adverse effects on β-cells \[[@CR61]\], elevated risk of hypoglycemia, tendency toward weight gain \[[@CR3], [@CR4]\], and limited effectiveness over time should be considered carefully \[[@CR62]\]. Compared with sulfonylureas, monotherapy studies with incretin-based therapies demonstrate better safety, and in the case of GLP-1RAs, better efficacy \[[@CR63], [@CR64]\].

Similarly, the author tends to choose incretins over thiazolidinediones (TZDs) in many patients because of the potential adverse effects of TZDs, including weight gain, peripheral edema, and increased risk of congestive heart failure \[[@CR3]\].

Incretins as Add-on Therapy {#Sec9}
===========================

Use of incretins in dual therapy may be considered after lifestyle and drug monotherapy become insufficient and before β-cell function ceases and insulin therapy becomes the only option.

Incretin Plus Metformin Therapy {#Sec10}
-------------------------------

In head-to-head studies comparing GLP1-RAs with DPP-4 inhibitors, incretin-based therapies have demonstrated modest to robust effects on glycemic indices in patients on metformin, with greater reductions in FPG and A1C with GLP1-RAs, compared with DPP-4 inhibitors. For example, in a head-to-head comparison of EQW with sitagliptin, in which each was used as add-on therapy to metformin, A1C reduction was significantly greater with EQW, overall, as well as among patients with A1C levels ≥9% \[[@CR19]\]. Similarly, in a head-to-head comparison of liraglutide and sitagliptin in patients with inadequate control on metformin, liraglutide was associated with significantly greater reductions in A1C, FPG, and body weight with a similar incidence of hypoglycemia \[[@CR12], [@CR13]\]. In both trials, nausea and vomiting were more common with GLP-1RAs than sitagliptin \[[@CR12], [@CR13], [@CR19]\].

Two studies have also compared the efficacy of liraglutide to exenatide BID \[[@CR22]\] and EQW \[[@CR24]\] in patients inadequately controlled on metformin, sulfonylurea, or both (in the exenatide BID trial) or metformin, sulfonylurea, and/or pioglitazone (in the EQW trial). In the first trial, liraglutide provided significantly greater improvements in A1C (1.1% vs 0.8%, *P* \< 0.0001) than EQW \[[@CR22]\]. While both agents were well tolerated, nausea was less persistent and hypoglycemia less frequent with liraglutide than with exenatide BID. When compared with EQW, liraglutide was associated with greater reductions in A1C (1.48% vs 1.28%) and body weight (3.6 vs 2.7 kg); however, EQW was associated with less nausea and vomiting \[[@CR24]\]. Reductions in systolic BP (SBP) were also similar between groups.

Blood pressure management is an important component of treatment in all patients with T2D \[[@CR65]\]. Liraglutide, exenatide BID, EQW, and sitagliptin generally show similar reductions in SBP, while diastolic BP is not affected \[[@CR12]--[@CR14], [@CR22], [@CR24], [@CR25]\]. One study of EQW showed greater reduction in SBP compared with sitagliptin \[[@CR19]\]. While BP reductions are generally beneficial and cardiovascular risk reduction is a priority in diabetes management, the author uses incretin therapies in their practice for their glycemic and weight effects and not their impact on BP.

Clinical Experience with Incretins as Add-on Therapy to Metformin {#Sec11}
-----------------------------------------------------------------

The use of incretin therapy as add-on therapy with metformin is recommended in treatment guidelines and it is the author's primary intervention in most patients on metformin whose A1C is above their target goal \[[@CR3], [@CR4]\]. The greater A1C reduction and weight loss associated with GLP-1RAs make them my preferred incretin therapy in most patients. Most of the author's patients lose approximately 3--4.5 kg on GLP-1RAs, but some may experience more dramatic weight reductions of up to 13--18 kg.

In fact, the need for weight loss may drive the choice of GLP1-RAs over DPP-4 inhibitors in some patients, and may persuade patients to choose injections over oral therapy. Moreover, DPP-4 inhibitors are postprandial modulators that may be less useful than longer-acting GLP1-RAs in patients with FPG \>200 mg/dL. When the injection barrier is insurmountable, DPP-4 inhibitors can be prescribed; however, patients should be actively involved in the decision-making process. In nonobese patients requiring \<1% reduction in A1C, a DPP-4 inhibitor can be used if the patient prefers. However, the author usually switches patients already on DPP-4 inhibitors to GLP-1RAs if they require an additional 0.5% A1C reduction.

Head-to-head clinical trials demonstrate that the more protracted agents have fewer GI symptoms, with exenatide BID causing the most GI symptoms, followed by liraglutide, and then EQW \[[@CR22], [@CR24], [@CR25]\]. In the author's experience, many patients who did not tolerate exenatide BID are able to successfully use liraglutide and EQW.

Before initiating any GLP-1RA, patients should be informed of the potential for GI AEs. To mitigate symptoms with exenatide and liraglutide, treatment should be initiated at a lower dose and titrated up to achieve maximal effect. For example, if patients experience nausea with liraglutide, the dose is increased only when the nausea is resolved. In the rare event that nausea remains an issue, the titration of the liraglutide dose can be slowed. This technique has been found to be effective, even though it is not specifically recommended in the labeling \[[@CR7]\]. EQW is not usually titrated, but the author's patients with nausea on exenatide BID do not use the 10-mcg dose until the nausea abates.

Incretin Plus Sulfonylurea Therapy {#Sec12}
----------------------------------

Both sulfonylureas and incretins stimulate release of insulin from pancreatic β-cells \[[@CR34], [@CR66]\]. Insulin release by sulfonylureas is glucose independent (primarily affects FPG) and increases the risk for hypoglycemia. Conversely, incretins stimulate insulin in a glucose-dependent manner, minimizing risk of hypoglycemia. Therefore, combining incretin therapy with a sulfonylurea potentially allows for lowering of the sulfonylurea dose and a possible reduction in the risk of hypoglycemia, while maintaining or increasing glycemic control \[[@CR5]--[@CR7], [@CR67]\]. While results from clinical trials indicate that adding an incretin to a sulfonylurea reduces A1C by 0.5--1.1% \[[@CR64], [@CR67], [@CR68]\], there are few data on the comparative impact of incretin agents in patients inadequately controlled on sulfonylureas alone.

In patients already using sulfonylureas who need an A1C reduction of 1--1.5%, the dose of sulfonylurea should be reduced when DPP-4 inhibitors or GLP-1RAs are added. However, the current sulfonylurea dose should be maintained if an A1C reduction of \>1.5% is needed. The author also asks patients receiving sulfonylurea therapy in combination with an incretin for an extra fingerstick glucose measurement before dinner.

Use of Incretins in Triple Therapy {#Sec13}
==================================

While guidelines often recommend insulin therapy as the preferred option for patients inadequately controlled on metformin and an additional agent, many patients receive triple therapy at this stage, particularly if they are reluctant to initiate insulin.

Incretin Plus Metformin and Sulfonylurea {#Sec14}
----------------------------------------

Although several studies have evaluated the use of incretin therapy in combination with metformin and a sulfonylurea, there have been no such head-to-head comparisons. In one study, liraglutide added to metformin and a sulfonylurea reduced A1C by 1.3% and decreased weight by 1.8 kg \[[@CR69]\]. A similar study of exenatide BID reported a reduction in A1C of 1.0% and a weight loss of 2.5% \[[@CR70]\]. In these trials, hypoglycemia was reported by 27% \[[@CR69]\] of patients on liraglutide and 27% of patients on exenatide \[[@CR70]\]. In a study evaluating sitagliptin in combination with metformin and a sulfonylurea, the combination reduced A1C by 0.9% but increased weight by 0.8 kg \[[@CR71]\]. The incidence of hypoglycemia with the sitagliptin combination was 16.4%.

The combination of metformin, sulfonylurea, and a GLP-1RA is the author's preferred noninsulin-based triple therapy, because this combination is effective in reducing A1C and FPG with few hypoglycemic events. To avoid hypoglycemia when using this combination, the sulfonylurea dose typically should be reduced when adding an incretin therapy.

Incretin Plus Metformin and TZD Therapy {#Sec15}
---------------------------------------

Adding GLP-1RA to TZD therapy for patients inadequately controlled with TZD and metformin leads to complementary effects: an increase in β-cell insulin secretory function (GLP-1RAs), inhibition of glucose production by the liver (metformin), and an increase in glucose uptake by muscle (TZD), and consequently, improved glycemic control \[[@CR72]\]. Combining incretins with TZDs may also mitigate the adverse effect of TZDs on weight. Data on the comparative use of incretin therapies with TZDs and metformin are limited. However, a study of liraglutide with metformin and a TZD reported a reduction in A1C of 1.5% with a reduction in weight of 1--2 kg and an incidence of hypoglycemia of 7.9--9.0% \[[@CR73]\].

Incretin Plus Insulin Therapy {#Sec16}
=============================

In many patients, addition of insulin to oral antidiabetic drugs (OADs) or GLP-1RAs is required to meet treatment goals. New studies demonstrate the utility of combining basal insulin with incretin therapies. When used in combination with GLP-1RAs or DPP-4 inhibitors, exogenous insulin is augmented with endogenous, glucose-dependent insulin secretion, allowing the body to compensate for increased carbohydrate intake without increasing the dose of exogenous insulin and, consequently, risk of hypoglycemia \[[@CR28], [@CR31]--[@CR33]\]. Complementary combination therapy can be accomplished by adding a short-acting incretin agent (exenatide) that primarily targets PPG to basal insulin that primarily targets FPG \[[@CR29]\].

Longer-acting liraglutide in combination with basal insulin has also shown to improve glycemic indices. Liraglutide targets both FPG and PPG, without the increase in hypoglycemia or weight gain associated with increased insulin dosing. Addition of GLP-1RAs allows for lowering the basal insulin dose and may even eliminate the need for prandial insulin \[[@CR15], [@CR29]\]. In fact, insulin doses should be reduced when initiating GLP-1RAs in patients on insulin. With DPP-4 inhibitors, the basal insulin dose stays the same since FPG changes are minimal \[[@CR31]--[@CR33]\]. Incretin therapies are useful in patients taking insulin, even if only to prevent the intensification of basal insulin regimens to multiple daily injections.

Long-term Safety of Incretin Therapies {#Sec17}
======================================

Pancreatitis {#Sec18}
------------

Pancreatitis has been reported in post-marketing surveillance for both GLP-1RAs and DPP-4 inhibitors \[[@CR74]\]. In patients with risk factors for pancreatitis, including gallstones, high triglycerides, or excessive alcohol intake, incretins should be used with caution. Liraglutide, exenatide BID, and EQW are not recommended in patients with a history of pancreatitis \[[@CR5]--[@CR7]\]. Before initiating incretin therapy, the possible risk for pancreatitis with patients should be discussed. Patients should be advised to contact their health care provider immediately if they experience severe abdominal pain. While careful observation for signs and symptoms of pancreatitis is recommended following incretin initiation, the totality of clinical, preclinical, and post-marketing evidence does not clearly substantiate an association between incretin therapies and acute pancreatitis, although published opinions on this topic differ \[[@CR75]--[@CR77]\]. The author has had no experience with pancreatitis in patients using incretin therapy. Moreover, experts convened by the National Institute of Diabetes and Digestive and Kidney Diseases in June 2013 concluded that there is likely no increased risk for pancreatic cancer associated with incretin therapies, although longer-term studies are needed \[[@CR78]\].

Thyroid Neoplasm {#Sec19}
----------------

Based on preclinical data, liraglutide and exenatide BID are absolutely contraindicated in patients with a personal or family history of medullary thyroid carcinoma and in patients with multiple endocrine neoplasia syndrome type 2 \[[@CR6], [@CR7]\]. Although rare (the author has seen medullary thyroid carcinoma three times in 25 years), the author recommends palpating the patient's thyroid gland to examine for nodules before starting therapy.

Conclusion {#Sec20}
==========

Incretins play an important role in normal glucose homeostasis, and incretin therapies should be considered in combination treatment regimens for patients with T2D from early onset to late disease. The selection of a particular agent should be individualized and depends on patient characteristics, preferences, and treatment goals, as well as differences in overall clinical profiles among incretin agents.

In clinical trials and in my own clinical experience, GLP-1RAs have shown greater and sustained glycemic control compared with DPP-4 inhibitors, with the additional benefits of weight loss and reduced SBP. High patient satisfaction has been reported with GLP-1RAs despite the subcutaneous route of administration \[[@CR38], [@CR79]--[@CR81]\]. In combination therapy with insulin, GLP-1RAs lead to sustained glycemic control, along with reduced insulin doses without increase in hypoglycemia or weight gain.

As a whole, the incretin class of antidiabetes agents is very useful, and both DPP-4 inhibitors and GLP-1RAs have improved T2D management. Many patients now consider injectable therapy in view of the observed benefits of GLP-1RAs and those who succeed with this therapy are satisfied with the results.
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